After a judicial battle of almost a decade, the pharmaceutical industry has regained the right to market vaccines with trademarks in Brazil.
In a landmark decision rendered on December 15, 2010 in Sindusfarma v ANVISA, the Court of Appeals for the First Circuit affirmed the district court’s decision and a preliminary injunction declaring the unconstitutionality of a rule of law dating from the 1970s: Article 5, § 4, of Law No. 6,360.
This provision states that “drugs containing a single well-known active ingredient, at the discretion of Ministry of Health, and immunotherapeutic drugs and pharmaceutical raw materials must be identified by their generic names provided in the Brazilian Pharmacopeia and cannot, under any circumstances, have marks or fantasy designations”.
The decision is a leading case in terms of both trademark and food and drug laws.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on email@example.com.